The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2021-03-17
Target enrollment:
Participant gender:
Summary
This is a phase 1, First-In-Human, open label study, trialing a new PARP (poly-ADP ribose
polymerase) inhibitor medication IMP4297 in participants with advanced solid tumour.